Christopher Coughlin - Allergan Plc Lead Independent Director

Director

Mr. Christopher J. Coughlin is Lead Independent Director of Allergan Plc. Mr. Coughlin joined the Board of Directors in July 2014 following the Companys acquisition of Forest Laboratories, Inc., having served as a member of the Board of Directors of Forest beginning 2011. Mr. Coughlin began serving as our Lead Independent Director in October 2016. Mr. Coughlin served as Senior Advisor to the CEO and Board of Directors of Tyco until September 2012. Prior to that, he was Executive Vice President and Chief Financial Officer of Tyco International from 2005 to 2010. During his tenure, he played a central role in the separation of Tyco into five independent, public companies. Prior to joining Tyco, he worked as the Chief Operating Officer of the Interpublic Group of Companies from June 2003 to December 2004, as Chief Financial Officer from August 2003 to June 2004 and as a director from July 2003 to July 2004. Previously, Mr. Coughlin was Executive Vice President and Chief Financial Officer of Pharmacia Corporation from 1998 until its acquisition by Pfizer in 2003. Prior to that, he was Executive Vice President of Nabisco Holdings and President of Nabisco International. From 1981 to 1996 he held various positions, including Chief Financial Officer, at Sterling Winthrop. In addition to the directorships listed below, Mr. Coughlin also previously served on the Board of Directors of Interpublic Group of Companies, Monsanto Company and Perrigo Company. since 2016.
Age 66
Tenure 8 years
Phone862 261 7000
Webhttp://www.allergan.com
Coughlin has a B.S. in accounting from Boston College.

Christopher Coughlin Latest Insider Activity

Tracking and analyzing the buying and selling activities of Christopher Coughlin against Allergan Plc stock is an integral part of due diligence when investing in Allergan Plc. Christopher Coughlin insider activity provides valuable insight into whether Allergan Plc is net buyers or sellers over its current business cycle. Note, Allergan Plc insiders must abide by specific rules, including filing SEC forms every time they buy or sell Allergan Plc'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Allergan Plc Management Efficiency

The company has Return on Asset of (0.0564) % which means that on every $100 spent on assets, it lost $0.0564. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0913) %, meaning that it generated no profit with money invested by stockholders. Allergan Plc's management efficiency ratios could be used to measure how well Allergan Plc manages its routine affairs as well as how well it operates its assets and liabilities.
The company has 23.08 B in debt with debt to equity (D/E) ratio of 39.4, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Allergan Plc has a current ratio of 0.98, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Debt can assist Allergan Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Allergan Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Allergan Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Allergan to invest in growth at high rates of return. When we think about Allergan Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Gretchen HaggertyTeleflex Incorporated
65
Carol EinigerBoston Properties
70
Richard FriedHudson Pacific Properties
53
Christy HaubeggerHudson Pacific Properties
52
Kelly AyotteBoston Properties
52
Richard PackerTeleflex Incorporated
62
William BoehmNeogen
70
John SchreiberHudson Pacific Properties
67
Jeffrey GravesTeleflex Incorporated
55
William WaltonBoston Properties
68
Diane HoskinsBoston Properties
62
James TobinNeogen
61
Alan PatricofBoston Properties
81
Ivan SeidenbergBoston Properties
68
John HeinmillerTeleflex Incorporated
66
Richard CrowderNeogen
56
Antonios IsaacLive Ventures
60
Stephen KlaskoTeleflex Incorporated
67
Charles FischerNeogen
73
Robert VahradianLGI Homes
56
Martin TurchinBoston Properties
77
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc. Allergan Plc operates under Drug Manufacturers - General classification in USA and is traded on BATS Exchange. It employs 17400 people. Allergan Plc (AGN) is traded on New York Stock Exchange in USA and employs 17,400 people.

Management Performance

Allergan Plc Leadership Team

Elected by the shareholders, the Allergan Plc's board of directors comprises two types of representatives: Allergan Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allergan. The board's role is to monitor Allergan Plc's management team and ensure that shareholders' interests are well served. Allergan Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allergan Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Matthew Walsh, Chief Financial Officer, Executive Vice President
Robert Bailey, Chief Legal Officer and Corporate Secretary
Robert Stewart, Executive VP and President of Generic and Global Operations
Ronald Taylor, Independent Director
Adriane Brown, Independent Director
William Meury, Executive Vice President, Chief Commercial Officer
Brenton Saunders, Chairman of the Board, President, Chief Executive Officer
Wayne Swanton, Executive Vice President - Global Operations
Robert Hugin, Independent Director
Nicholson, Chief R&D Officer
Christopher Bodine, Independent Director
Karen Ling, Chief Human Resource Officer, Executive Vice President
Michael Gallagher, Lead Independent Director
Paul Bisaro, Executive Chairman
Thomas Freyman, Independent Director
Catherine Klema, Lead Independent Director
James DArecca, Chief Accounting Officer
Christopher Coughlin, Lead Independent Director
Nesli Basgoz, Independent Director
Philippe Schaison, Executive Vice President and President Allergan Medical
Maria Hilado, CFO and Executive VP
Joseph Boccuzi, Independent Director
Patrick OSullivan, Independent Director
Fred Weiss, Independent Director
A Bailey, Executive Vice President, Chief Legal Officer and Corporate Secretary
Alex Kelly, Chief Communications Officer
CDavid Nicholson, Executive Vice President, Chief R&D Officer
Carol Davidson, Independent Director
Michael Greenberg, Independent Director
Ron Taylor, Independent Director
Jonathon Kellerman, Executive Vice President Chief Compliance Officer
Paul Navarre, Executive Vice President and President International Brands
James Bloem, Independent Director
Karina Calzadilla, IR Contact Officer
Peter McDonnell, Independent Director

Allergan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allergan Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Allergan Plc in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Allergan Plc's short interest history, or implied volatility extrapolated from Allergan Plc options trading.

Pair Trading with Allergan Plc

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allergan Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allergan Plc will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Simon Property could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Simon Property when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Simon Property - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Simon Property Group to buy it.
The correlation of Simon Property is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Simon Property moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Simon Property Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Simon Property can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Allergan Plc information on this page should be used as a complementary analysis to other Allergan Plc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Other Consideration for investing in Allergan Stock

If you are still planning to invest in Allergan Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Allergan Plc's history and understand the potential risks before investing.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
FinTech Suite
Use AI to screen and filter profitable investment opportunities
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Global Correlations
Find global opportunities by holding instruments from different markets
CEOs Directory
Screen CEOs from public companies around the world
Insider Screener
Find insiders across different sectors to evaluate their impact on performance